Keratinocyte Carcinoma (Skin Cancer) - Causes, Treatment & When to See a Doctor

```html

What is Keratinocyte Carcinoma (Skin Cancer)?

Keratinocyte carcinoma (KC) is an umbrella term for the two most common types of skin cancer that arise from keratin‑producing cells in the epidermis:

• Basal cell carcinoma (BCC) – originates in the basal layer of the epidermis.
• Squamous cell carcinoma (SCC) – originates in the squamous cells of the outer epidermis.

Although both are called “skin cancer,” they differ from melanoma, which develops from pigment‑producing melanocytes. KCs are usually slow‑growing, rarely spread (metastasize) when caught early, and are highly curable with proper treatment. According to the American Cancer Society, more than 5 million cases of KC are diagnosed each year in the United States—far more than any other cancer type.<sup>1</sup>

Common Causes

Keratinocyte carcinoma results from a combination of genetic, environmental, and lifestyle factors that damage DNA in skin cells. The most important contributors are:

• Ultraviolet (UV) radiation – especially UV‑B (280‑320 nm) from sun exposure and tanning beds.
• Chronic sun‑damage – actinic keratoses, solar lentigines, and “field cancerization” of sun‑exposed skin.
• Immunosuppression – organ‑transplant recipients, HIV infection, or long‑term corticosteroid use.
• Fair skin, red or blond hair, blue/green eyes – less melanin means less natural UV protection.
• Genetic syndromes – e.g., Gorlin syndrome (basal cell nevus syndrome), xeroderma pigmentosum, or familial SCC.
• Exposure to chemical carcinogens – arsenic in drinking water or occupational exposure, tar, coal, and certain pesticides.
• Chronic skin inflammation or injury – long‑standing scars, burns, or ulcerated wounds (Marjolin ulcer).
• Human papillomavirus (HPV) infection – especially high‑risk HPV types for SCC of the anogenital region and, less commonly, the hand.
• Radiation therapy – prior therapeutic radiation can trigger SCC in the treated field years later.
• Age – risk rises sharply after age 50, reflecting cumulative UV exposure.

Associated Symptoms

Keratinocyte carcinoma may be asymptomatic early on, but several visual and sensory clues often appear:

• New or changing papule, nodule, or plaque on sun‑exposed areas (face, ears, neck, hands, arms).
• Shiny, pearl‑like bump – classic for BCC.
• Persistent, scaly, or crusted lesion – typical of SCC.
• Ulceration or bleeding that does not heal within 2–3 weeks.
• Raised “rolled” border around a central ulcer (BCC).
• Redness, swelling, or tenderness around the lesion.
• Itching or burning sensation—especially in lesions that become inflamed.
• Appearance of multiple lesions – many patients develop several KCs over time.

When to See a Doctor

Any skin change that meets the “ABCDE” criteria or persists beyond a few weeks warrants prompt evaluation:

• Asymmetry – one half of the lesion looks different from the other.
• Border – irregular, ragged, or poorly defined edges.
• Color – varying shades of brown, black, pink, red, or white.
• Diameter – larger than 6 mm (about the size of a pencil eraser), though many KCs are smaller.
• Evolving – any change in size, shape, color, or symptomatology.

Additional red flags include bleeding, oozing, crusting, or pain that does not resolve, especially on the lips, ears, or genitalia. If you notice any of these features, schedule a dermatology appointment promptly. Early detection dramatically improves cure rates and reduces the need for extensive surgery.<sup>2</sup>

Diagnosis

Diagnosing KC involves a stepwise approach performed by a dermatologist or qualified primary‑care provider:

1. Clinical Examination

The clinician inspects the skin under magnification (dermatoscope) to evaluate pattern, vascular structures, and margins. High‑resolution photography may be used to track changes over time.

2. Skin Biopsy

Definitive diagnosis requires histologic confirmation. Common biopsy techniques include:

• Punch biopsy – a circular tool removes a full‑thickness skin sample.
• Incisional or excisional biopsy – the entire lesion is removed (preferred for small lesions).
• Shave biopsy – a superficial layer is taken; may be enough for BCC but can miss deeper SCC invasion.

Pathology reports classify the tumor (BCC vs. SCC), depth of invasion, grade (well‑ vs. poorly‑differentiated), and presence of perineural involvement—information essential for treatment planning.<sup>3</sup>

3. Staging (for SCC)

While BCC rarely requires formal staging, SCC may be staged with the AJCC (American Joint Committee on Cancer) system based on tumor size, depth, perineural invasion, and whether it has spread to nodes or distant sites.

4. Additional Tests (rare)

If the lesion appears high‑risk or metastatic disease is suspected, imaging (ultrasound, CT, MRI, or PET) and sentinel lymph‑node biopsy may be ordered.

Treatment Options

Treatment is individualized according to tumor type, size, location, patient health, and cosmetic considerations. Options range from simple office‑based procedures to more extensive surgery.

Standard Medical Treatments

• Surgical Excision – the gold standard for most BCCs and SCCs; removes the tumor with a margin of healthy tissue (4‑6 mm for low‑risk BCC, up to 10 mm for high‑risk SCC).
• Mohs Micrographic Surgery – stepwise excision with immediate microscopic examination; offers the highest cure rate (up to 99 %) and maximal tissue preservation, ideal for facial or high‑risk lesions.
• Curettage & Electrodesiccation (C&E) – scraping the tumor followed by cauterization; useful for low‑risk BCCs on low‑visibility areas.
• Topical Therapies –
  • 5‑Fluorouracil (5‑FU) – applied 2‑4 times daily for 2‑4 weeks; effective for superficial BCC and actinic keratoses.
  • Imiquimod – immune response modifier used 5‑times weekly for 6 weeks (superficial BCC) or longer for SCC in situ.
• Photodynamic Therapy (PDT) – photosensitizing cream applied, then activated with a specific light source; particularly useful for superficial BCC and widespread actinic keratoses.
• Radiation Therapy – external beam radiation for patients who can’t undergo surgery (e.g., elderly, poor wound healing) or as adjuvant therapy for positive margins.
• Systemic Therapies (advanced disease) –
  • Hedgehog pathway inhibitors (vismodegib, sonidegib) for metastatic or locally advanced BCC.
  • PD‑1 inhibitors (cemiplimab) for advanced SCC not amenable to surgery or radiation.

Home and Supportive Care

• Keep the wound clean and covered as instructed after surgery.
• Apply prescribed topical agents exactly as directed; avoid over‑use which can cause irritation.
• Use silicone gel sheets or scar‑reduction creams (e.g., silicone gels, vitamin E) after the wound has fully healed to minimize scarring.
• Stay hydrated, maintain a balanced diet rich in antioxidants (vitamins C, E, and beta‑carotene) to support skin healing.

Prevention Tips

Because UV exposure is the dominant risk factor, most KCs are preventable with protective habits:

• Sun protection – apply broad‑spectrum SPF 30+ sunscreen 15 minutes before exposure; reapply every 2 hours, or after swimming/sweating.
• Protective clothing – wear wide‑brim hats, UV‑protective sunglasses, long‑sleeved shirts, and pants.
• Avoid peak UV hours – seek shade between 10 am and 4 pm when UV intensity peaks.
• Never use indoor tanning beds – they emit concentrated UV‑B and increase KC risk up to 70 %.
• Regular skin checks – perform monthly self‑exams and schedule annual dermatologist exams, especially if you have a personal or family history of skin cancer.
• Treat actinic keratoses promptly – these precancerous lesions can evolve into SCC if left untreated.
• Quit smoking – smoking impairs immune surveillance and is an independent risk factor for SCC.
• Protect immunocompromised patients – limit sun exposure, use higher‑SPF sunscreens, and consider prophylactic topical agents as directed by a dermatologist.
• Monitor occupational exposures – use protective gear when working with arsenic, coal tar, or other known carcinogens.

Emergency Warning Signs

Key Take‑aways

Keratinocyte carcinoma, encompassing basal cell and squamous cell cancers, is the most common skin malignancy but is highly treatable when caught early. Understanding risk factors, performing regular self‑checks, and using sun‑safe habits are the most powerful tools to prevent disease. If a skin change raises any suspicion—especially a non‑healing sore, a shiny bump, or a scaly patch—consult a dermatologist promptly. Early diagnosis, appropriate pathology, and tailored treatment (often Mohs surgery or simple excision) provide cure rates exceeding 95 % for most patients.

References

1. American Cancer Society. Skin Cancer Facts & Figures. 2024. https://www.cancer.org
2. Mayo Clinic. Basal cell carcinoma - Symptoms and causes. Updated 2023. https://www.mayoclinic.org
3. National Cancer Institute. Squamous Cell Skin Cancer Treatment (PDQ®)–Health Professional Version. 2022. https://www.cancer.gov
4. Cleveland Clinic. How to Prevent Skin Cancer. 2023. https://my.clevelandclinic.org
5. World Health Organization. Ultraviolet radiation and the INTERSUN program. 2021. https://www.who.int

```